FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2275952218> ?p ?o ?g. }

• W2275952218 endingPage "81" @default.
• W2275952218 startingPage "73" @default.
• W2275952218 abstract "Objectives Non-small-cell-lung-cancer (NSCLC) patients harbouring epidermal growth factor receptor (EGFR) mutations develop drug resistance after 9–12 months of EGFR tyrosine kinase inhibitors (TKIs) therapy pointing out the issue of the second-line treatment choice. Materials and methods From June 2009 until May 2013 patients affected by advanced NSCLC harbouring EGFR mutations receiving first-line TKI were collected mainly retrospectively in 24 Italian Centers. Primary objective was to describe the percentage of EGFR mutated patients receiving second-line therapy after progression to first-line EGFR-TKIs assessing the type, the activity in terms of objective response rate (ORR), efficacy in terms of progression free survival (PFS) and overall survival (OS), and safety of second-line treatment. Secondary objective was to describe the efficacy of first-line EGFR-TKIs. Results 312 patients were included. Most of them were females (203, 65.1%), never smokers (200, 64.1%), with adenocarcinoma histology (290, 92.9%). The most common mutations were EGFR exon 19 deletion and L858R, detected in 186 and 97 cases (59.6% and 31.1%), respectively. At data cut-off, 274 patients (95.1%) received any second-line treatment (including best supportive care or local treatments only). A total of 163 patients received second-line systemic therapy with an ORR of 20.9% (95% CI:14.62–27.10), a median PFS and OS of 4.7 (95% CI:3.81–5.26) and 24.5 (95% CI:21.65–27.37) months, respectively. Grade 3–4 hematological and non-hematological toxicities were reported in 9% and 6.3% of 144 patients treated with chemotherapy while non-hematological toxicity was reported in 4 cases of the 17 patients receiving second-line target agents. Conclusions BE-Positive is the first multicenter observational study reporting outcomes of therapies in a “real-life Caucasian EGFR-mutated population”, highlighting the need of further researches about new treatment strategies in this setting." @default.
• W2275952218 created "2016-06-24" @default.
• W2275952218 creator A5001428569 @default.
• W2275952218 creator A5004048756 @default.
• W2275952218 creator A5007575010 @default.
• W2275952218 creator A5008661123 @default.
• W2275952218 creator A5011655337 @default.
• W2275952218 creator A5017022820 @default.
• W2275952218 creator A5021158045 @default.
• W2275952218 creator A5021357646 @default.
• W2275952218 creator A5025797878 @default.
• W2275952218 creator A5026639715 @default.
• W2275952218 creator A5032078755 @default.
• W2275952218 creator A5033351253 @default.
• W2275952218 creator A5034267169 @default.
• W2275952218 creator A5043174098 @default.
• W2275952218 creator A5046270433 @default.
• W2275952218 creator A5046939478 @default.
• W2275952218 creator A5051933262 @default.
• W2275952218 creator A5052130645 @default.
• W2275952218 creator A5053244829 @default.
• W2275952218 creator A5053651576 @default.
• W2275952218 creator A5055722979 @default.
• W2275952218 creator A5061610276 @default.
• W2275952218 creator A5064646828 @default.
• W2275952218 creator A5071783009 @default.
• W2275952218 creator A5072619943 @default.
• W2275952218 creator A5077553499 @default.
• W2275952218 creator A5078056877 @default.
• W2275952218 creator A5086055266 @default.
• W2275952218 date "2016-05-01" @default.
• W2275952218 modified "2023-10-18" @default.
• W2275952218 title "BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients" @default.
• W2275952218 cites W1969038428 @default.
• W2275952218 cites W1974036277 @default.
• W2275952218 cites W1988827171 @default.
• W2275952218 cites W2027242209 @default.
• W2275952218 cites W2030227571 @default.
• W2275952218 cites W2031486360 @default.
• W2275952218 cites W2040299716 @default.
• W2275952218 cites W2065477010 @default.
• W2275952218 cites W2096198395 @default.
• W2275952218 cites W2101569260 @default.
• W2275952218 cites W2104700583 @default.
• W2275952218 cites W2111191667 @default.
• W2275952218 cites W2111662961 @default.
• W2275952218 cites W2113521542 @default.
• W2275952218 cites W2125409964 @default.
• W2275952218 cites W2125665528 @default.
• W2275952218 cites W2126177831 @default.
• W2275952218 cites W2129360604 @default.
• W2275952218 cites W2131914710 @default.
• W2275952218 cites W2132870547 @default.
• W2275952218 cites W2133149289 @default.
• W2275952218 cites W2135192471 @default.
• W2275952218 cites W2141032252 @default.
• W2275952218 cites W2149733252 @default.
• W2275952218 cites W2152481222 @default.
• W2275952218 cites W2163885776 @default.
• W2275952218 cites W2210071992 @default.
• W2275952218 cites W4238604577 @default.
• W2275952218 doi "https://doi.org/10.1016/j.lungcan.2016.02.011" @default.
• W2275952218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27040855" @default.
• W2275952218 hasPublicationYear "2016" @default.
• W2275952218 type Work @default.
• W2275952218 sameAs 2275952218 @default.
• W2275952218 citedByCount "15" @default.
• W2275952218 countsByYear W22759522182017 @default.
• W2275952218 countsByYear W22759522182018 @default.
• W2275952218 countsByYear W22759522182019 @default.
• W2275952218 countsByYear W22759522182020 @default.
• W2275952218 countsByYear W22759522182021 @default.
• W2275952218 countsByYear W22759522182022 @default.
• W2275952218 countsByYear W22759522182023 @default.
• W2275952218 crossrefType "journal-article" @default.
• W2275952218 hasAuthorship W2275952218A5001428569 @default.
• W2275952218 hasAuthorship W2275952218A5004048756 @default.
• W2275952218 hasAuthorship W2275952218A5007575010 @default.
• W2275952218 hasAuthorship W2275952218A5008661123 @default.
• W2275952218 hasAuthorship W2275952218A5011655337 @default.
• W2275952218 hasAuthorship W2275952218A5017022820 @default.
• W2275952218 hasAuthorship W2275952218A5021158045 @default.
• W2275952218 hasAuthorship W2275952218A5021357646 @default.
• W2275952218 hasAuthorship W2275952218A5025797878 @default.
• W2275952218 hasAuthorship W2275952218A5026639715 @default.
• W2275952218 hasAuthorship W2275952218A5032078755 @default.
• W2275952218 hasAuthorship W2275952218A5033351253 @default.
• W2275952218 hasAuthorship W2275952218A5034267169 @default.
• W2275952218 hasAuthorship W2275952218A5043174098 @default.
• W2275952218 hasAuthorship W2275952218A5046270433 @default.
• W2275952218 hasAuthorship W2275952218A5046939478 @default.
• W2275952218 hasAuthorship W2275952218A5051933262 @default.
• W2275952218 hasAuthorship W2275952218A5052130645 @default.
• W2275952218 hasAuthorship W2275952218A5053244829 @default.
• W2275952218 hasAuthorship W2275952218A5053651576 @default.
• W2275952218 hasAuthorship W2275952218A5055722979 @default.
• W2275952218 hasAuthorship W2275952218A5061610276 @default.
• W2275952218 hasAuthorship W2275952218A5064646828 @default.

• next